The board of directors (the “Board”) of the Sino Biopharmaceutical Limited (the “Company”, together with its subsidiaries, the “Group”) announced that two innovative drugs “Anlotinib Hydrochloride Capsules” and “TQB2916 (CD40 agonist)”, developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“Chia Tai Tianqing”), a subsidiary of the Company, will be presented at the Annual Meeting 2024 of American Association for Cancer Research (AACR) for their 5 study results.

**Clinical studies:**

Anlotinib: gastrointestinal tumor  
No.: CT213/13  
Title of abstract: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C

Anlotinib: small cell lung cancer  
No.: 5098/20  
Title of abstract: Second-line treatment outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients after first-line immuno-chemotherapy

TQB2916: advanced malignancies  
No.: CT192/20  
Title of abstract: A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies
Fundamental studies:

Anlotinib: medullary thyroid carcinoma
No.: 4665/18
Title of abstract: USP18 promotes anlotinib resistance in medullary thyroid carcinoma by stabilizing aurora B kinase

Anlotinib: advanced ovarian cancer
No.: 3997/6
Title of abstract: PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer

About Anlotinib:
Anlotinib Hydrochloride Capsules is a novel oral small molecule multi-targeted tyrosine kinase inhibitor (TKI) independently developed by Chia Tai Tianqing, which can effectively inhibit VEGFR 1-3, PDGFR α / β, FGFR 1-4, c-Kit and other kinases, and achieves inhibition of tumor neovascularization, inhibition of tumor growth, and modulation of the immune microenvironment by regulating the reprogramming of tumor microenvironment. In May 2018, Anlotinib Hydrochloride Capsules was approved for marketing by the National Medical Products Administration ("NMPA") and was the first drug approved for utilisation in the third-line treatment of advanced non-small cell lung cancer in China. Anlotinib Hydrochloride Capsules have been approved for five indications in China: third-line non-small cell lung cancer, third-line small cell lung cancer, soft tissue sarcoma, medullary thyroid cancer and differentiated thyroid cancer. In January 2023, the application for the sixth indication of Anlotinib Hydrochloride Capsules for use in combination with Benmelstobart “TQB2450 (PD-L1 Inhibitor)” and chemotherapy for the first-line treatment of small cell lung cancer has been accepted by the Center for Drug Evaluation (the “CDE”) of the NMPA. In February 2024, the marketing application for the seventh indication of Anlotinib Hydrochloride Capsules was officially accepted by the CDE, for use in combination with Benmelstobart for the treatment of recurrent or metastatic endometrial cancer.
About TQB2916 (CD40 agonist):
CD40 agonists play a tumor suppressor role by activating antigen-presenting cells (APCs) and promoting the activation of immune cells. TQB2916 is a fully human IgG2 monoclonal antibody that targets CD40 and was shown in in vitro pharmacodynamic results to activate B cells and dendritic cells, which in turn activate T cells to secrete IFN-γ. Preclinical in vivo pharmacodynamic results showed that TQB2916 significantly inhibited tumor growth in animal models. Currently, there is no CD40 agonist approved for marketing in the world, and similar products show potential development prospects in pancreatic cancer, soft tissue sarcoma, melanoma, esophageal cancer and other fields.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 March 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.